Result card

  • ECO5: What are the estimated differences in costs and outcomes between IGG and its comparator(s)?
English

What are the estimated differences in costs and outcomes between IGG and its comparator(s)?

Authors: Anna-Theresa Renner, Neill Booth, Esther Kraft, Ingrid Rosian-Schikuta, Matthias Schwenkglenks

Internal reviewers: Pseudo297 Pseudo297

Given the lack of available data and lack of published evidence on the efficacy and/or the effectiveness of the intervention, the researchers (and internal reviewers) of this ‘Costs and economic evaluation’ domain agreed that it would not be prudent to undertake research into costs or undertake an economic evaluation.

Renner A et al. Result Card ECO5 In: Renner A et al. Costs and economic evaluation In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 31 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267